4 Nov 2009 14:38
For release: 4 November 2009
Epistem Plc
("Epistem" or the "Company")
Posting of Annual Report and Accounts
Epistem Plc (LSE: EHP), the rapidly growing UK biotechnology company with adult epithelial stem cell expertise in oncology, gastrointestinal and dermatological diseases, confirms that its Annual Report and Accounts for the year ended 30 June 2009 and notice of AGM were posted to shareholders on 2 November 2009.
An electronic copy of the Annual Report and Accounts is available on the Investor Centre section of the Company's website, www.epistem.co.uk.
For further details, please contact:
Epistem Plc
Matthew Walls CEO +44 (0) 161 606 7258
John Rylands CFO
Piper Jaffray Ltd.
Neil Mackison, Graeme Smethurst +44 (0) 0203 142 8700
Corporate Broking: Jamie Adams
Mike Wort / Anna Dunphy +44 (0) 207 861 3838
De Facto Communications
About Epistem:
Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal diseases, dermatology and ageing. Epistem provides specialised pre-clinical efficacy testing, biomarker services and develops proprietary novel therapeutics for partnership and development with drug development companies.
Genedrive (GDR)